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ABSTRACT: Recently, we described a role for the circadian clock protein and nuclear receptor Rev-erbα in regulating glial activation states
in the brain. Deletion of Rev-erbα resulted in microglial as well as astrocytic activation, while a Rev-erbα agonist diminished the severity of
lipopolysaccharide (LPS)-induced neuroinflammation. Concomitant with this glial activation is impaired neuronal health. These findings suggest
that Rev-erb proteins may play critical roles in glial biology. Pertinent ideas such as the glial cell type of most importance, the translatability
of these findings to human disease, and the effect of manipulating Rev-erbs in models of neurodegeneration, need to be explored further. In
this commentary, we will address the potential role of Rev-erbs in neuroinflammation related to neurodegenerative diseases and speculate on
Rev-erbs as potential therapeutic targets for these conditions.
Keywords: Circadian, Rev-erb alpha, microglia, neuroinflammation
RECEIVED: April 25, 2019. ACCEPTED: April 30, 2019.
Type: Commentary
Funding: The author(s) disclosed receipt of the following financial support for the research,
authorship, and/or publication of this article: This work was funded by NIH grant R01AG054517.
Declaration of conflicting interests: The author(s) declared no potential
conflicts of interest with respect to the research, authorship, and/or publication of this article.

In a recent article,1 our group described a role for the circadian protein Rev-erbα in regulating glial activation. We demonstrate time-of-day oscillations in microglial morphology/
activation that are abrogated by the global deletion of Reverbα, which appears to lock microglia in an activated state.
Transcriptomic changes in the hippocampus of Rev-erbα KO
(RKO) mice also showed upregulation in inflammatory gene
expression and activation of pathways associated with inflammation, including the NF-κB pathway. As Rev-erbα is a dedicated transcriptional repressor, we performed ChIP analyses
and found that Rev-erbα bound to the promoter regions of
NF-kB-related genes, including TRAF2 and IKBA, and may
directly regulate NF-kB activation. In vivo, astrocytes are also
activated in RKO mice. However, whereas RKO primary
microglia are activated at baseline in vitro, RKO primary
astrocytes are not. These data suggest a cell-autonomous role for
Rev-erbα in microglial activation, and a cell non-autonomous
effect on astrocytes. RKO-mediated neuroinflammation
resulted in impairments to neuronal health in vitro and on a
global brain network level. Using the Rev-erb agonist SR9009,
we showed that the Rev-erb pathway can be targeted to mitigate lipopolysaccharide (LPS)-induced neuroinflammation in
vitro and in vivo. While this article presents all the detrimental
effects of deleting Rev-erbα, we explored a more nuanced
view on the results in this commentary.
Rev-erbα has previously been shown to regulate peripheral innate immunity.2 Macrophages play a critical role in
peripheral innate immunity. Given the role of Rev-erbα in
macrophages, we explored how Rev-erbα could affect microglial function/activation. Classically, macrophage and microglial activation have been classified using the M1/M2
dichotomy. The M1 state is associated with neurotoxicity,
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whereas the M2 is associated with neurotrophic effects.3
Recent advances in transcriptomic analyses have challenged
this classification. Our RKO microglia do not clearly fit into
either of these categories. On one hand, we noted increases in
the classical NF-κB signaling cascade that would suggest an
M1 state. However, our microarray and CD68 staining data
would suggest increases in phagocytic capacity, which suggests an M2 state. This further illustrates the idea that microglial activation exists on a spectrum and is not so easily
classified dichotomously. Rev-erbα deletion may induce a
hybrid activation state that needs to be explored in future
studies employing microglial-specific transcriptomics. Recent
work also suggested that activated microglia can induce neurotoxic A1 astrocyte activation.4 Our data indicate that astrocyte activation in RKO mice does not fully recapitulate the
gene expression changes of an A1 or A2 astrocyte activation
state, although most pan-reactive transcripts are increased.
Rev-erbα functions as a nuclear receptor and repressor that
recruits HDAC3 through NCoR.5 The loss of this repressive
element in the epigenome may prime glia to be more reactive
to innocuous stimuli, resulting in spontaneous glial activation
and neuroinflammation.
In addition to their homeostatic functions, microglia have
recently gained attention for their potential causative role in
neurodegenerative pathogenesis. Recent genome-wide association studies indicated that mutations in microglial and
phagocytosis genes are highly associated with increased
Alzheimer disease (AD) risk.6 One of those genes is TREM2,
which we found to be upregulated in the hippocampus of
RKO mice. Of note, TREM2 is a damage-associated microglial gene which is upregulated in microglia surrounding amyloid plaques.7 Deletion of TREM2 is known to impair
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Figure 1. Considerations for the targeting of Rev-erbs in neurodegenerative diseases. Hypothetical model showing the balance between modulating glial
activation and altering various aspects of neurodegenerative disease. As noted, activation of Rev-erbs could limit glial activation, which might exert
protective effects of synaptic health, but could exacerbate Aβ and tau accumulation. The effects of Rev-erb may be modulated by circadian influence, as
well as stage of disease.

microglial responses to amyloid plaques and disrupt microglial
synapse elimination.
Rev-erbα deletion is also associated with increased microglial
phagocytic activation—as seen by increased CD68/Iba1 colocalization in RKO microglia. Other work has also shown that
increases in microglial CD68 can result in increased synaptic
pruning in the hippocampus.8 These suggest that Rev-erbα in
microglia can potentially regulate synaptic elimination, perhaps through regulation of TREM2. Although Aβ plaque and
Tau tangle formation are the classical neuropathological hallmarks of AD, decline in synaptic health has been found to be
most closely correlated with cognitive decline.9 Thus, deeper
understanding of the processes that affect synaptic health is
critical. Given the increases in phagocytic capacity of RKO
microglia, it is reasonable to hypothesize a decline in synaptic
health in AD models lacking Rev-erbα. However, the effects
may not be so straightforward. Increases in microglial phagocytosis can result in reduced Aβ burden in the brain,10 but can
also exacerbate Tau pathology.11 To fully understand the role
of Rev-erbα in disease, further studies are necessary. However,
we speculate that drug interventions through Rev-erbα could
influence neurodegenerative pathogenesis through modulation of glial function.
Rev-erbα is a heme/lithium sensitive nuclear receptor
that functions as part of the circadian clock molecular
machinery.12 Given this, Rev-erb activity can be modulated
using existing agonists and antagonists, including SR900913
and SR8278.14 We used SR9009 in vivo and in vitro and
found that it was effective in mitigating LPS-induced neuroinflammation. SR9009 has favorable pharmacokinetics and
can readily cross the blood brain barrier. However, the
potency of SR9009 is relatively low, as micromolar quantities
are required in vitro to exert effects, thus opening the door to

off-target effects. With regard to suppressing LPS-induced
inflammation, we observed that the efficacy of SR9009 was
greatly reduced in RKO mice, suggesting that SR9009 is
indeed acting through Rev-erbα in this setting. Our data, as
well as data from other groups,15 provide proof of principle
that pharmacologic targeting Rev-erbα can mitigate LPSinduced neuroinflammation and support the development of
high-affinity agents.
Although results from our group and others15 are encouraging, there is a considerable knowledge gap that must be
addressed before attempting to predict the effect of Rev-erb
targeted drugs in neurodegenerative diseases. First, LPSinduced neuroinflammation is very different than the inflammation observed in neurodegenerative diseases. As an
example, TREM2 is suppressed by LPS, but is upregulated
by amyloid plaque pathology. Thus, the effects of Rev-erbα
manipulation will need to be tested in neurodegenerative
models, as the effects on specific pathways may be quite different. Second, simply reducing neuroinflammation may not
be enough to ameliorate neurodegenerative sequelae, as glial
activation can exert differing effects on various aspects of
pathology at different points in disease course. Using AD as
an example, inhibiting neuroinflammation through Reverbα activation could abolish the early protective effects provided by increased phagocytic capacity, as more phagocytic
microglia could clear plaques and tangles more efficiently
and delay the onset of neurodegeneration. Conversely, Reverbα activation could provide protection from synapse loss
later in the disease course. In addition, continuous activation/blockade of Rev-erbα could be detrimental since our
data show that microglial activation cycles by time of
day, and these cycles may be important for normal brain
homeostasis. Finally, aged microglia are primed and exhibit
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decreased phagocytosis and exaggerated responses to stimuli.
Therefore, targeting microglial Rev-erbα in aged animals or
people would further compromise their ability to function as
phagocytes. This suggests that we would need to consider 2
axes of time when considering using Rev-erbα—time of day
and time course of the disease. To fully leverage Rev-erbα as
a therapeutic target in neurodegenerative disease, all of the
outlined factors have to be considered. A summary of the
ideas illustrated is in Figure 1.
Although this commentary begins to consider the potential
implications of targeting Rev-erbα in neurodegenerative disease, more in vivo studies are required. On a more fundamental
level, future studies need to determine the cell type specificity of
Rev-erbα in mediating neuroinflammation. Our studies were
done in global RKO mice and could have contributing effects
from peripheral immune cells or neuronal damage. Future studies need to parse out the effects of knocking out Rev-erbα in
only microglia or astrocytes. Regarding the role of Rev-erb in
neurodegeneration, studies are needed to examine the effect of
Rev-erbα manipulation, either genetic or pharmacologic, in
mouse models that address multiple aspects of pathology.
Finally, the impact of these interventions on cellular circadian
clocks and sleep cycles will need to be addressed. Although this
area of investigation is still in its infancy, Rev-erb-targeted
drugs may present a novel avenue for optimizing glial responses
in neurodegenerative and other neurological disease.
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